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Background and Significance
Chemoprophylaxis and therapeutic in-
tervention of the HIV epidemic requires
understanding the mechanisms by which
newly assembled HIV-1 virions are re-
leased from infected cells. This knowledge
may prove diagnostic in identifying unsus-
pected sites for intervention and plausible
strategies for targeted drug delivery. It is
imperative, urgent, and ethical to uncover
reliable and selective inhibitors of progeny
virus release [1].
Vpu, an accessory membrane protein
from the AIDS-associated virus HIV-1 [2],
folds into two distinct structural domains
with different biological activities: a trans-
membrane (TM) a-helical domain in-
volved in the budding of new virions from
infected cells, and a cytoplasmic domain
encompassing two amphipathic helices,
which is implicated in CD4 degradation
[3,4]. Without Vpu, the HIV-1 virus
remains attached to the surface of the
human cell in which it has replicated. This
activity of Vpu requires an intact TM a-
helical domain [5,6]. And, it is known that
oligomerization of the Vpu TM domain
results in the formation of sequence-
specific, cation-selective channels [6–9].
The molecular mechanism by which Vpu
facilitates virion release remains unclear
[2]. However, the recent discovery that
Vpu neutralizes the effect of tetherin (B
cell stromal antigen 2, BST-2/HM1.24)
has provided insights into the molecular
basis of its action [10,11]. Tetherin is an
interferon-induced host cell membrane
protein that blocks the release of HIV-1
virions from the cell surface [10,11]. This
finding posits the notion that abrogation of
Vpu function with the consequent sup-
pression of new viable virus release from
the host cell surface is a plausible thera-
peutic strategy in the treatment of HIV/
AIDS.
Hypothesis
We propose that it is feasible to increase
the effective cell surface density of Vpu-
free tetherin by designing transmembrane
peptide decoys that target the Vpu TM a-
helix [4,6–9] and abort the assembly of
tetherin-Vpu heterooligomers. The conse-
quence of this intervention would be to
accrue two populations of Vpu in HIV-1-
infected cells: one available for complex
formation with tetherin and capable of
enhancing the release of new virions, and
a second population scavenged in hetero-
meric complexes with the decoys that
would inhibit Vpu binding to tetherin
and restrict virion release.
TM peptide decoy design involves
identification of sequences that would fold
in the proximity of the Vpu TM helix and
conform complementary matching surfac-
es to secure tight binding to Vpu and
thereby generate unproductive, mem-
brane-embedded heteromers. It requires
exploring the TM sequence landscape to
identify optimal Vpu TM matchmakers
that would self-assemble into unproductive
heterooligomers, thereby overcoming the
restrain on tetherin and the consequent
restriction of virion release from infected
cells. A more refined design would entail
identifying sequences that effectively em-
body intrinsically unfolded conformers
[12] that on contact with the Vpu TM
adopt secondary structure and bind to
complementary surfaces, rendering Vpu
unavailable for binding to tetherin. The
TM decoys are designed to bury their
internal complexity and interact with
other TM modules through simple inter-
faces by surface matching. Fold design
must be compatible with the environment
to afford its intended function. For mem-
brane proteins, such interfaces must nec-
essarily be complementary with and ad-
justed to both the hydrophobic core of the
lipid bilayer and to the amphipathic
character prevalent at the bilayer–water
interfaces. A vast number of sequences
may underlie such design and be compat-
ible with the bilayer constrains; the
challenge is identification.
Rationale
Tetherin [10,13] and Vpu [3,4,6,14]
exhibit a strong propensity to oligomerize.
It is precisely this proclivity which consti-
tutes the essence of the self-assembly of the
Vpu channel [15] and of the Vpu–tetherin
heterooligomers that underlies Vpu-de-
pendent virion release [10,11]. At the root
is the question of coupling, namely how
the TM modules of Vpu and tetherin self-
assemble into stable heteromers. The
structural underpinning of such assembly
is the TM region of Vpu and tetherin.
These two proteins may represent a limit
of simplicity: a single TM a-helix per
polypeptide with an inherent propensity to
oligomerize. The beauty of this essential
design resides in the fact that both channel
activity and virion release activity are
thermodynamic consequences of the nat-
ural tendency of the membrane-embedded
TM helix to aggregate in order to optimize
its interactions within the hydrophobic
interior of the lipid bilayer, thereby
generating a helical bundle, i.e., the
structural blueprint for the channel
[15,16] and the Vpu–tetherin heterooligo-
mer [10,11]. Vpu TM matchmakers
would consequently abort the Vpu–
tetherin partnership by co-opting the
match, converging on a common mecha-
nism.
The rationale underlying this hypothesis
is strengthened by a number of additional
facts: (1) The intact TM of Vpu is required
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antagonize the tetherin-dependent reten-
tion of nascent enveloped virus [11]. (2)
The Vpu TM assembles into tetramers
that express ion channel activity which
requires an intact TM sequence [7]. (3)
The TM of Vpu can be functionally
substituted by the TM of the M2 proton
channel of influenza virus and yield a
pathogenic virus [17]. The implication is
that the M2 TM assembles into productive
heterooligomers [18,19] with the Vpu TM
and thereby promotes retention of virions
attached to tetherin. (4) Overexpression of
TASK-1, an acid-sensitive K
+ channel,
markedly impairs the ability of Vpu to
enhance virion release [20]. The implica-
tion is that the high sequence similarity of
Vpu and TASK-1 TMs promotes the
assembly of unproductive heterooligo-
mers, thereby rendering Vpu incompetent
in virion release. (5) A 20-residue peptide
corresponding to the C-proximal region of
a1-antitrypsin blocks HIV-1 entry by
interacting with the gp41 fusion peptide
[21]. The binary complex is associated
primarily by hydrophobic interactions
between complementary matching surfac-
es. Small molecules from ‘‘credit card’’
libraries inhibit gp41-mediated cell fusion
by disrupting protein–protein interactions
underlying the gp41 six-helix bundle
formation [22,23]. These findings lend
credence to the hypothesis that short
peptide segments derived from the TM
of tetherin or similar TM sequences, and
small hydrophobic compounds targeted to
the Vpu TM, act as Vpu inhibitors by
binding to complementary surfaces, there-
by supporting the retention by tetherin of
newly assembled virions at cell surfaces.
This hypothesis naturally leads us to
outline an initial itinerary to identify the
minimal sequence determinants for the
folding and coupling between decoy and
Vpu TM modules that would minimally
entail the following: (1) Identification of
Vpu TM matchmakers by sequence anal-
ysis. The selection criteria consider exper-
imentally determined TM a-helices or
predicted single TM spans with a high
propensity to fold into a-helices, and a
high sequence similarity to the Vpu TM a-
helix. A truncated alignment of relevant
TMs with the target sequence of Vpu TM
a-helix, as determined by NMR spectros-
copy [4,9,24] is illustrated in Figure 1. The
TM of the M2 proton channel of influenza
A virus was selected using the NMR [19]
and crystal [18] structures. The TM
segments of TASK-1 [20] and tetherin
[10,11,25] are based on secondary struc-
ture predictions. The anti-aIIb sequence is
an optimized result obtained using the
analysis dubbed CHAMP (computed heli-
cal anti-membrane protein), a computa-
tional approach to design peptides that
specifically recognize the TM helices of
natural proteins in a sequence-specific
mode [26]. This alignment is remarkable
insofar as it highlights the occurrence of a
conserved sequence motif compatible with
a propensity for intramembrane self-as-
sembly, a requirement for Vpu TM
matchmakers. (2) Implementation of the
CHAMP [26] analysis combined with
integration of the symmetry principles
emerging from designed protein–protein
associations [27] and the aid of computa-
tional refinement focusing on positions of
side-chains for favorable pairwise interac-
tions. This should provide a robust
method to identify optimal Vpu match-
maker decoys. (3) Structure-based design
of additional peptide decoy sequences.
The atomic structures of the TM a-helix
of Vpu [4,9,15,24] and of the influenza
M2 proton channel [18,19] provide blue-
prints to examine their critical interactions
and should accelerate the design process.
This strategy is not limited to the use of a
single peptide; combinations may be
superior and, ultimately, a cocktail of
peptides could be the target to develop.
(4) Assessment of the specificity of the
design, including the evaluation of control
peptide decoy sequences consisting of the
same amino acid composition as the test
decoy peptides with randomized sequence
[6,11]. (5) An approach that is not limited
to the use of peptides. Peptidomimetics are
a valid option, as shown by the discovery
of a blocker of the N-methyl-D-aspartate
(NMDA) receptor channel using combi-
natorial libraries [28]. (6) Small molecule
‘‘credit card’’ libraries. These are akin to
credit cards in terms of being planar,
aromatic core structures decorated with
chemical diversity that confers on them
the feature of inserting into crevices at the
interacting surfaces, thereby disrupting the
complementarity that underlies the speci-
ficity of association [22,23]. (7) Peptides
that could be readily generated by solid-
phase methods [6,24], and circular di-
chroism used to assess a-helical content
[29]. (8) Lead compounds that could be
validated based on structure-activity rela-
tionships assessing their inhibitory activity
on the Vpu-enhanced progeny virus
release from CD4
+ human T cell line
A3.01 or HeLa cells infected with HIV-1
clone NL4-3 [5,6,11,30]. Optimal candi-
dates would suggest structural and chem-
ical scaffolds to be used as blueprints for
refinement.
Concluding Remarks
The guiding principle underpinning this
hypothesis outlines a new way of thinking
about disrupting protein–protein interac-
tions by focusing on the TM anchors of
the partners, a hitherto unexplored path
towards the development of more effective
blockers of virus release that may generate
novel leads that could be developed into
specific, realistic, and effective medica-
tions.
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Figure 1. Identification Vpu TM Matchmakers by Sequence Analysis (http://www.ncbi.nih.gov). Selected sequences are displayed
(FASTA) and aligned using ClustalW. A single letter code for the amino acid residues is used. Numbers denote residue position in the corresponding
sequence. Residue similarity is shaded using the PAM250 substitution matrix appropriate for identifying conserved residues in the alignment of
evolutionary distant sequences. Accession numbers are as follows: HIV-1 Vpu, Swiss-Prot entry P05921; M2 influenza, gi 58531181; TASK-1, gi
82542571; BST-2/HM1.24/Tetherin, gi 4757876; anti-aII, designed protein (see [26]).
doi:10.1371/journal.ppat.1000246.g001
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